Stock Track | UroGen Pharma Soars 5.67% in Pre-market on Strong Q1 Earnings Beat and 152% Revenue Growth

Stock Track

05/06

UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.

The biotech company reported a quarterly loss of $0.47 per share, beating the consensus estimate of a $0.48 loss. More impressively, revenue soared to $50.96 million, a 152% year-over-year increase that handily surpassed the $44.82 million analyst forecast. The company's net loss also narrowed substantially compared to the same period last year.

The strong performance was driven primarily by the successful commercial launch of ZUSDURI, supported by a permanent J Code that took effect in January 2026 and improved reimbursement. Additionally, JELMYTO revenue grew 7% year-over-year. The company maintained its full-year 2026 guidance and remains on track for an NDA submission for UGN-103 in the second half of the year, contributing to positive investor sentiment.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1174571892"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174571892\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174571892?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174571892","market":"sg","top_or_hot":-1,"title":"Stock Track | UroGen Pharma Soars 5.67% in Pre-market on Strong Q1 Earnings Beat and 152% Revenue Growth","media":"Stock Track","content":"<p>UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.</p><p>The biotech company reported a quarterly loss of $0.47 per share, beating the consensus estimate of a $0.48 loss. More impressively, revenue soared to $50.96 million, a 152% year-over-year increase that handily surpassed the $44.82 million analyst forecast. The company's net loss also narrowed substantially compared to the same period last year.</p><p>The strong performance was driven primarily by the successful commercial launch of ZUSDURI, supported by a permanent J Code that took effect in January 2026 and improved reimbursement. Additionally, JELMYTO revenue grew 7% year-over-year. The company maintained its full-year 2026 guidance and remains on track for an NDA submission for UGN-103 in the second half of the year, contributing to positive investor sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | UroGen Pharma Soars 5.67% in Pre-market on Strong Q1 Earnings Beat and 152% Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | UroGen Pharma Soars 5.67% in Pre-market on Strong Q1 Earnings Beat and 152% Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 21:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.</p><p>The biotech company reported a quarterly loss of $0.47 per share, beating the consensus estimate of a $0.48 loss. More impressively, revenue soared to $50.96 million, a 152% year-over-year increase that handily surpassed the $44.82 million analyst forecast. The company's net loss also narrowed substantially compared to the same period last year.</p><p>The strong performance was driven primarily by the successful commercial launch of ZUSDURI, supported by a permanent J Code that took effect in January 2026 and improved reimbursement. Additionally, JELMYTO revenue grew 7% year-over-year. The company maintained its full-year 2026 guidance and remains on track for an NDA submission for UGN-103 in the second half of the year, contributing to positive investor sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"URGN","symbol_name":"乌龙制药","start_time":0,"source_url":"","article_id":"1174571892","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174571892","pubTimestamp":1778073147,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"URGN":"乌龙制药"},"translate_title":"个股追踪|UroGen Pharma盘前飙升5.67%，Q1盈利强劲，营收增长152%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"URGN":1},"content_text":"UroGen Pharma Ltd. (URGN) saw its stock surge 5.67% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.The biotech company reported a quarterly loss of $0.47 per share, beating the consensus estimate of a $0.48 loss. More impressively, revenue soared to $50.96 million, a 152% year-over-year increase that handily surpassed the $44.82 million analyst forecast. The company's net loss also narrowed substantially compared to the same period last year.The strong performance was driven primarily by the successful commercial launch of ZUSDURI, supported by a permanent J Code that took effect in January 2026 and improved reimbursement. Additionally, JELMYTO revenue grew 7% year-over-year. The company maintained its full-year 2026 guidance and remains on track for an NDA submission for UGN-103 in the second half of the year, contributing to positive investor sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}